A Case of Tislelizumab-associated Fulminant Myocarditis Diagnosed by Myocardial Biopsy
10.3969/j.issn.1000-3614.2025.03.014
- VernacularTitle:经心肌活检诊断替雷利珠单抗相关暴发性心肌炎一例
- Author:
Maihemuti AYINUER
1
;
Jie YUAN
;
Rui CHEN
;
Lingmin WU
;
Xuejing DUAN
;
Hui CHENG
;
Xiaoliang LUO
Author Information
1. 新疆维吾尔自治区人民医院 心脏及泛血管医学诊疗中心,乌鲁木齐 830001
- Publication Type:Journal Article
- Keywords:
endomyocardial biopsy;
tislelizumab;
fulminant myocarditis;
immune checkpoint inhibitor-associated myocarditis
- From:
Chinese Circulation Journal
2025;40(3):293-296
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors are effective tumor treatment agents with survival benefits.However,immune toxicity to various organs has become a new challenge in clinical practice.The cardiac involvement can be presented as heart failure,arrhythmia(atrial fibrillation,atrioventricular block,bundle branch block,ventricular tachycardia,etc.),myocardial-pericarditis,myocardiopathy,and sudden cardiac death,etc.This patient developed abnormally increased myocardial enzymes,impaired cardiac function,and atrioventricular block after 1-month treatment with tislelizumab.Endomyocardial biopsy examination confirmed the diagnosis of immune checkpoint inhibitor-associated myocarditis.Through the diagnosis,treatment,and review of relevant literatures of this case,we wish to improve the understanding of immune checkpoint inhibitor-associated myocarditis,and therefore improve the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis for clinicians.
